Treatment Resistant Major Depressive Disorder
7
0
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
28.6%
2 terminated out of 7 trials
60.0%
-26.5% vs benchmark
29%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
DBS of the Lateral Habenula in Treatment-Resistant Depression
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial
This is a Study to Determine the Antidepressant Effects of AZD6765